Anti-Müllerian hormone as a potential marker of pubertal suppression in girls with central precocious puberty treated with GnRH agonists
Journal of Pediatric Endocrinology and Metabolism · 19.11.2026
DOI: 10.1515/jpem-2026-0747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, online erschienen am 19.11.2026. Verfasst von Cemil Kocyigit und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology, University of Health Sciences, İzmir Tepecik Training and Research Hospital, İzmir, Türkiye. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Objectives
To compare serum anti-Müllerian hormone (AMH) levels among girls with central precocious puberty (CPP) receiving gonadotropin-releasing hormone agonist (GnRH-a) treatment and prepubertal and pubertal controls, and to investigate the association between AMH levels and pubertal suppression.
Methods
This cross-sectional study included 50 GnRH-a–treated girls with CPP and 25 prepubertal and 25 pubertal controls. Pubertal suppression was assessed using three predefined criteria: reduced bone age advancement, stable/regressed breast Tanner stage, and annual height velocity ≤6 cm/year. Patients meeting 2–3 or 0–1 criteria were classified as having an adequate or inadequate pubertal suppression profile, respectively.
Results
AMH differed significantly among the groups (p=0.002) and was higher in CPP [2.93 (2.24–4.24) µg/L] than in pubertal controls [1.60 (1.05–2.72) µg/L; Bonferroni-adjusted p=0.003]. Among patients with CPP, 76 % had an adequate pubertal suppression profile. AMH was higher in patients with an adequate than an inadequate pubertal suppression profile [3.67 (2.53–4.70) vs. 2.56 (1.98–2.94) µg/L; p=0.028]. Suppression profiles also differed in anthropometric measures and GnRH-a exposure. Higher AMH was associated with stable/regressed breast Tanner stage (p=0.014) and height velocity ≤6 cm/year (p=0.034), but not reduced bone age advancement (p=0.763). AMH discriminated adequate and inadequate pubertal suppression profiles (AUC 0.714, 95 % CI 0.553–0.875; p=0.009); an exploratory threshold of ≥3.00 μg/L yielded 60.5 % sensitivity and 83.3 % specificity.
Conclusions
Serum AMH was higher in GnRH-a–treated girls with CPP than in pubertal controls and was associated with an adequate pubertal suppression profile. AMH may be a complementary biomarker for assessing pubertal suppression, although prospective validation is required.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pediatric Endocrinology, University of Health Sciences, İzmir Tepecik Training and Research Hospital, İzmir, Türkiye.
ORCID-Profile: Cemil Kocyigit
Zitieren
APA
Kocyigit, C., Celik, T. C., Karaca, S. E., Cevizbas, T. T., & Acar, S. (2026). Anti-Müllerian hormone as a potential marker of pubertal suppression in girls with central precocious puberty treated with GnRH agonists. Journal of Pediatric Endocrinology and Metabolism. https://doi.org/10.1515/jpem-2026-0747
Vancouver
Kocyigit C, Celik TC, Karaca SE, Cevizbas TT, Acar S. Anti-Müllerian hormone as a potential marker of pubertal suppression in girls with central precocious puberty treated with GnRH agonists. Journal of Pediatric Endocrinology and Metabolism. 2026. doi:10.1515/jpem-2026-0747
BibTeX
@article{Kocyigit2026,
author = {Kocyigit, Cemil and Celik, Tugce Candan and Karaca, Seda Erisen and Cevizbas, Tugce Tiric and Acar, Sezer},
title = {Anti-Müllerian hormone as a potential marker of pubertal suppression in girls with central precocious puberty treated with GnRH agonists},
journal = {Journal of Pediatric Endocrinology and Metabolism},
year = {2026},
doi = {10.1515/jpem-2026-0747}
}
EUVIMED